ID   GALC_HUMAN              Reviewed;         685 AA.
AC   P54803; B4DKE8; B4DYN1; B4DZJ8; B7Z7Z2; J3KN25; J3KPP8; Q8J030;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   08-JUN-2016, sequence version 3.
DT   10-MAY-2017, entry version 161.
DE   RecName: Full=Galactocerebrosidase;
DE            Short=GALCERase;
DE            EC=3.2.1.46;
DE   AltName: Full=Galactocerebroside beta-galactosidase;
DE   AltName: Full=Galactosylceramidase;
DE   AltName: Full=Galactosylceramide beta-galactosidase;
DE   Flags: Precursor;
GN   Name=GALC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT THR-562.
RX   PubMed=7601472; DOI=10.1016/0888-7543(95)80230-J;
RA   Luzi P., Rafi M.A., Wenger D.A.;
RT   "Structure and organization of the human galactocerebrosidase (GALC)
RT   gene.";
RL   Genomics 26:407-409(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9434153; DOI=10.1016/S0167-4781(97)00140-1;
RA   Sakai N., Fukushima H., Inui K., Fu L., Nishigaki T., Yanagihara I.,
RA   Tatsumi N., Ozono K., Okada S.;
RT   "Human galactocerebrosidase gene: promoter analysis of the 5'-flanking
RT   region and structural organization.";
RL   Biochim. Biophys. Acta 1395:62-67(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 4 AND 5), NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 2-685 (ISOFORM 3), AND VARIANTS CYS-184
RP   AND THR-562.
RC   TISSUE=Testis, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ALA-641.
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S.,
RA   Sun H., Du H., Pepin K., Artiguenave F., Robert C., Cruaud C.,
RA   Bruels T., Jaillon O., Friedlander L., Samson G., Brottier P.,
RA   Cure S., Segurens B., Aniere F., Samain S., Crespeau H., Abbasi N.,
RA   Aiach N., Boscus D., Dickhoff R., Dors M., Dubois I., Friedman C.,
RA   Gouyvenoux M., James R., Madan A., Mairey-Estrada B., Mangenot S.,
RA   Martins N., Menard M., Oztas S., Ratcliffe A., Shaffer T., Trask B.,
RA   Vacherie B., Bellemere C., Belser C., Besnard-Gonnet M.,
RA   Bartol-Mavel D., Boutard M., Briez-Silla S., Combette S.,
RA   Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., Muselet D.,
RA   Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P., Trybou A.,
RA   Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L.,
RA   Verdier J., Verdier-Discala C., Hillier L.W., Fulton L., McPherson J.,
RA   Matsuda F., Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W.,
RA   Quetier F., Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 2-685 (ISOFORM 1), PROTEIN SEQUENCE OF
RP   43-75 AND 452-470, CATALYTIC ACTIVITY, AND FUNCTION.
RC   TISSUE=Testis;
RX   PubMed=8281145; DOI=10.1093/hmg/2.11.1841;
RA   Chen Y.Q., Rafi M.A., de Gala G., Wenger D.A.;
RT   "Cloning and expression of cDNA encoding human galactocerebrosidase,
RT   the enzyme deficient in globoid cell leukodystrophy.";
RL   Hum. Mol. Genet. 2:1841-1845(1993).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 5-685 (ISOFORM 1), AND PARTIAL PROTEIN
RP   SEQUENCE.
RC   TISSUE=Placenta, and Skin fibroblast;
RX   PubMed=8297359; DOI=10.1006/bbrc.1994.1071;
RA   Sakai N., Inui K., Fujii N., Fukushima H., Nishimoto J.,
RA   Yanagihara I., Isegawa Y., Iwamatsu A., Okada S.;
RT   "Krabbe disease: isolation and characterization of a full-length cDNA
RT   for human galactocerebrosidase.";
RL   Biochem. Biophys. Res. Commun. 198:485-491(1994).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 15-685 (ISOFORM 1), AND
RP   VARIANT THR-562.
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 43-61 AND 452-470, PARTIAL PROTEIN SEQUENCE,
RP   FUNCTION, CATALYTIC ACTIVITY, AND TISSUE SPECIFICITY.
RC   TISSUE=Urine;
RX   PubMed=8399327; DOI=10.1016/0005-2760(93)90175-9;
RA   Chen Y.Q., Wenger D.A.;
RT   "Galactocerebrosidase from human urine: purification and partial
RT   characterization.";
RL   Biochim. Biophys. Acta 1170:53-61(1993).
RN   [9]
RP   REVIEW ON GLD MUTATIONS.
RX   PubMed=9338580;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:4<268::AID-HUMU2>3.0.CO;2-D;
RA   Wenger D.A., Rafi M.A., Luzi P.;
RT   "Molecular genetics of Krabbe disease (globoid cell leukodystrophy):
RT   diagnostic and clinical implications.";
RL   Hum. Mutat. 10:268-279(1997).
RN   [10]
RP   REVIEW ON VARIANTS.
RX   PubMed=10833326; DOI=10.1006/mgme.2000.2990;
RA   Wenger D.A., Rafi M.A., Luzi P., Datto J., Costantino-Ceccarini E.;
RT   "Krabbe disease: genetic aspects and progress toward therapy.";
RL   Mol. Genet. Metab. 70:1-9(2000).
RN   [11]
RP   VARIANT CYS-184.
RX   PubMed=7581365; DOI=10.1093/hmg/4.8.1285;
RA   Rafi M.A., Luzi P., Chen Y.Q., Wenger D.A.;
RT   "A large deletion together with a point mutation in the GALC gene is a
RT   common mutant allele in patients with infantile Krabbe disease.";
RL   Hum. Mol. Genet. 4:1285-1289(1995).
RN   [12]
RP   VARIANTS GLD ALA-318 AND GLY-566.
RX   PubMed=8595408; DOI=10.1093/hmg/4.10.1865;
RA   Tatsumi N., Inui K., Sakai N., Fukushima H., Nishimoto J.,
RA   Yanagihara I., Nishigaki T., Tsukamoto H., Fu L., Taniike M.,
RA   Okada S.;
RT   "Molecular defects in Krabbe disease.";
RL   Hum. Mol. Genet. 4:1865-1868(1995).
RN   [13]
RP   VARIANTS GLD HIS-79; SER-111; LEU-117; THR-250; SER-284 AND CYS-314,
RP   AND VARIANT THR-562.
RX   PubMed=8940268;
RA   De Gasperi R., Gama Sosa M.A., Sartorato E.L., Battistini S.,
RA   MacFarlane H., Gusella J.F., Krivit W., Kolodny E.H.;
RT   "Molecular heterogeneity of late-onset forms of globoid-cell
RT   leukodystrophy.";
RL   Am. J. Hum. Genet. 59:1233-1242(1996).
RN   [14]
RP   ERRATUM.
RA   De Gasperi R., Gama Sosa M.A., Sartorato E.L., Battistini S.,
RA   MacFarlane H., Gusella J.F., Krivit W., Kolodny E.H.;
RL   Am. J. Hum. Genet. 60:1264-1264(1997).
RN   [15]
RP   VARIANTS GLD ASN-544 AND SER-599.
RX   PubMed=8786069; DOI=10.1007/BF02185759;
RA   Rafi M.A., Luzi P., Zlotogora J., Wenger D.A.;
RT   "Two different mutations are responsible for Krabbe disease in the
RT   Druze and Moslem Arab populations in Israel.";
RL   Hum. Genet. 97:304-308(1996).
RN   [16]
RP   VARIANTS GLD MET-82; ASP-286 AND SER-634, AND VARIANTS VAL-305 AND
RP   THR-562.
RX   PubMed=9272171; DOI=10.1007/s004390050532;
RA   Furuya H., Kukita Y.-J., Nagano S., Sakai Y., Yamashita Y.,
RA   Fukuyama H., Inatomi Y., Saito Y., Koike R., Tsuji S., Fukumaki Y.,
RA   Hayashi K., Kobayashi T.;
RT   "Adult onset globoid cell leukodystrophy (Krabbe disease): analysis of
RT   galactosylceramidase cDNA from four Japanese patients.";
RL   Hum. Genet. 100:450-456(1997).
RN   [17]
RP   VARIANTS GLD ASP-286 AND ARG-553, VARIANT ALA-641, AND
RP   CHARACTERIZATION OF VARIANT GLD ASP-286.
RX   PubMed=10477434;
RX   DOI=10.1002/(SICI)1098-1004(1999)14:3<256::AID-HUMU9>3.0.CO;2-6;
RA   De Gasperi R., Gama Sosa M.A., Sartorato E.L., Battistini S.,
RA   Raghavan S., Kolodny E.H.;
RT   "Molecular basis of late-life globoid cell leukodystrophy.";
RL   Hum. Mutat. 14:256-262(1999).
RN   [18]
RP   VARIANTS GLD ARG-59; PHE-68; ILE-278; CYS-335; GLY-426; HIS-531 AND
RP   ARG-668.
RX   PubMed=10234611; DOI=10.1023/A:1005449919660;
RA   Fu L., Inui K., Nishigaki T., Tatsumi N., Tsukamoto H., Kokubu C.,
RA   Muramatsu T., Okada S.;
RT   "Molecular heterogeneity of Krabbe disease.";
RL   J. Inherit. Metab. Dis. 22:155-162(1999).
RN   [19]
RP   VARIANT GLD SER-41.
RX   PubMed=17579360; DOI=10.1002/humu.9500;
RA   Lissens W., Arena A., Seneca S., Rafi M., Sorge G., Liebaers I.,
RA   Wenger D., Fiumara A.;
RT   "A single mutation in the GALC gene is responsible for the majority of
RT   late onset Krabbe disease patients in the Catania (Sicily, Italy)
RT   region.";
RL   Hum. Mutat. 28:742-742(2007).
RN   [20]
RP   VARIANTS GLD LYS-130; ARG-318; ARG-323; THR-384; LEU-396 AND ASN-490,
RP   AND VARIANTS PRO-21; CYS-184; ASN-248; THR-562 AND ALA-641.
RX   PubMed=20886637; DOI=10.1002/humu.21367;
RA   Tappino B., Biancheri R., Mort M., Regis S., Corsolini F., Rossi A.,
RA   Stroppiano M., Lualdi S., Fiumara A., Bembi B., Di Rocco M.,
RA   Cooper D.N., Filocamo M.;
RT   "Identification and characterization of 15 novel GALC gene mutations
RT   causing Krabbe disease.";
RL   Hum. Mutat. 31:E1894-E1914(2010).
RN   [21]
RP   VARIANT GLD MET-681.
RX   PubMed=23462331; DOI=10.1016/j.gene.2013.02.010;
RA   Yang Y., Ren X., Xu Q., Wang C., Liu H., He X.;
RT   "Four novel GALC gene mutations in two Chinese patients with Krabbe
RT   disease.";
RL   Gene 519:381-384(2013).
CC   -!- FUNCTION: Hydrolyzes the galactose ester bonds of
CC       galactosylceramide, galactosylsphingosine, lactosylceramide, and
CC       monogalactosyldiglyceride. Enzyme with very low activity
CC       responsible for the lysosomal catabolism of galactosylceramide, a
CC       major lipid in myelin, kidney and epithelial cells of small
CC       intestine and colon. {ECO:0000269|PubMed:8281145,
CC       ECO:0000269|PubMed:8399327}.
CC   -!- CATALYTIC ACTIVITY: D-galactosyl-N-acylsphingosine + H(2)O = D-
CC       galactose + N-acylsphingosine. {ECO:0000269|PubMed:8281145,
CC       ECO:0000269|PubMed:8399327}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is 4.0-4.4.;
CC       Temperature dependence:
CC         Activity is lost after heating at 52 degrees Celsius for five
CC         minutes.;
CC   -!- SUBCELLULAR LOCATION: Lysosome.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=P54803-1; Sequence=Displayed;
CC       Name=3;
CC         IsoId=P54803-3; Sequence=VSP_036976;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=P54803-4; Sequence=VSP_036974;
CC         Note=Ref.3 (BAG64110) sequence is in conflict in position:
CC         17:A->T. {ECO:0000305};
CC       Name=5;
CC         IsoId=P54803-5; Sequence=VSP_036975, VSP_036977;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Detected in urine. Detected in testis, brain
CC       and placenta (at protein level). Detected in kidney and liver.
CC       {ECO:0000269|PubMed:8399327}.
CC   -!- POLYMORPHISM: Polymorphic amino-acid changes are responsible for
CC       the wide range of catalytic activities found in the general
CC       population.
CC   -!- DISEASE: Leukodystrophy, globoid cell (GLD) [MIM:245200]: An
CC       autosomal recessive disorder characterized by insufficient
CC       catabolism of several galactolipids that are important for normal
CC       myelin production. Four clinical forms are recognized. The
CC       infantile form accounts for 90% of cases. It manifests before six
CC       months of age with irritability, spasticity, arrest of motor and
CC       mental development, and bouts of temperature elevation without
CC       infection. This is followed by myoclonic jerks of arms and legs,
CC       oposthotonus, hypertonic fits, and mental regression, which
CC       progresses to a severe decerebrate condition with no voluntary
CC       movements and death from respiratory infections or cerebral
CC       hyperpyrexia before 2 years of age. Cases with later onset present
CC       with unexplained blindness, weakness and sensorimotor peripheral
CC       neuropathy, mental deterioration and death.
CC       {ECO:0000269|PubMed:10234611, ECO:0000269|PubMed:10477434,
CC       ECO:0000269|PubMed:17579360, ECO:0000269|PubMed:20886637,
CC       ECO:0000269|PubMed:23462331, ECO:0000269|PubMed:8595408,
CC       ECO:0000269|PubMed:8786069, ECO:0000269|PubMed:8940268,
CC       ECO:0000269|PubMed:9272171}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 59 family.
CC       {ECO:0000305}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-17 is the initiator.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA16645.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAA80975.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAH36518.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAA04971.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAA04972.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAA04972.1; Type=Miscellaneous discrepancy; Note=Probable intron retention.; Evidence={ECO:0000305};
CC       Sequence=BAA24902.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAG59160.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L38559; AAA80975.1; ALT_INIT; Genomic_DNA.
DR   EMBL; L38544; AAA80975.1; JOINED; Genomic_DNA.
DR   EMBL; L38545; AAA80975.1; JOINED; Genomic_DNA.
DR   EMBL; L38546; AAA80975.1; JOINED; Genomic_DNA.
DR   EMBL; L38547; AAA80975.1; JOINED; Genomic_DNA.
DR   EMBL; L38548; AAA80975.1; JOINED; Genomic_DNA.
DR   EMBL; L38549; AAA80975.1; JOINED; Genomic_DNA.
DR   EMBL; L38550; AAA80975.1; JOINED; Genomic_DNA.
DR   EMBL; L38551; AAA80975.1; JOINED; Genomic_DNA.
DR   EMBL; L38552; AAA80975.1; JOINED; Genomic_DNA.
DR   EMBL; L38553; AAA80975.1; JOINED; Genomic_DNA.
DR   EMBL; L38555; AAA80975.1; JOINED; Genomic_DNA.
DR   EMBL; L38556; AAA80975.1; JOINED; Genomic_DNA.
DR   EMBL; L38557; AAA80975.1; JOINED; Genomic_DNA.
DR   EMBL; L38558; AAA80975.1; JOINED; Genomic_DNA.
DR   EMBL; D86181; BAA24902.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AK296530; BAG59160.1; ALT_INIT; mRNA.
DR   EMBL; AK302519; BAG63793.1; -; mRNA.
DR   EMBL; AK302683; BAH13778.1; -; mRNA.
DR   EMBL; AK302956; BAG64110.1; -; mRNA.
DR   EMBL; AL136501; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL157955; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; L23116; AAA16645.1; ALT_INIT; mRNA.
DR   EMBL; D25283; BAA04971.1; ALT_INIT; mRNA.
DR   EMBL; D25284; BAA04972.1; ALT_SEQ; mRNA.
DR   EMBL; BC036518; AAH36518.1; ALT_INIT; mRNA.
DR   CCDS; CCDS55936.1; -. [P54803-3]
DR   CCDS; CCDS55937.1; -. [P54803-4]
DR   CCDS; CCDS9878.2; -. [P54803-1]
DR   PIR; I54205; I54205.
DR   RefSeq; NP_000144.2; NM_000153.3. [P54803-1]
DR   RefSeq; NP_001188330.1; NM_001201401.1. [P54803-3]
DR   RefSeq; NP_001188331.1; NM_001201402.1. [P54803-4]
DR   UniGene; Hs.513439; -.
DR   ProteinModelPortal; P54803; -.
DR   SMR; P54803; -.
DR   BioGrid; 108854; 12.
DR   STRING; 9606.ENSP00000261304; -.
DR   SwissLipids; SLP:000000644; -.
DR   CAZy; GH59; Glycoside Hydrolase Family 59.
DR   iPTMnet; P54803; -.
DR   PhosphoSitePlus; P54803; -.
DR   BioMuta; GALC; -.
DR   DMDM; 229462868; -.
DR   EPD; P54803; -.
DR   PaxDb; P54803; -.
DR   PeptideAtlas; P54803; -.
DR   PRIDE; P54803; -.
DR   DNASU; 2581; -.
DR   Ensembl; ENST00000261304; ENSP00000261304; ENSG00000054983. [P54803-1]
DR   Ensembl; ENST00000393568; ENSP00000377198; ENSG00000054983. [P54803-3]
DR   Ensembl; ENST00000393569; ENSP00000377199; ENSG00000054983. [P54803-4]
DR   Ensembl; ENST00000544807; ENSP00000437513; ENSG00000054983. [P54803-5]
DR   GeneID; 2581; -.
DR   KEGG; hsa:2581; -.
DR   UCSC; uc010tvz.2; human. [P54803-1]
DR   CTD; 2581; -.
DR   DisGeNET; 2581; -.
DR   GeneCards; GALC; -.
DR   GeneReviews; GALC; -.
DR   H-InvDB; HIX0026669; -.
DR   HGNC; HGNC:4115; GALC.
DR   HPA; CAB022196; -.
DR   MalaCards; GALC; -.
DR   MIM; 245200; phenotype.
DR   MIM; 606890; gene.
DR   neXtProt; NX_P54803; -.
DR   OpenTargets; ENSG00000054983; -.
DR   Orphanet; 206448; Adult Krabbe disease.
DR   Orphanet; 206436; Infantile Krabbe disease.
DR   Orphanet; 206443; Late-infantile/juvenile Krabbe disease.
DR   PharmGKB; PA28530; -.
DR   eggNOG; ENOG410IITE; Eukaryota.
DR   eggNOG; ENOG410XTIS; LUCA.
DR   GeneTree; ENSGT00390000003303; -.
DR   HOGENOM; HOG000068033; -.
DR   HOVERGEN; HBG005800; -.
DR   InParanoid; P54803; -.
DR   KO; K01202; -.
DR   PhylomeDB; P54803; -.
DR   TreeFam; TF312985; -.
DR   Reactome; R-HSA-1660662; Glycosphingolipid metabolism.
DR   ChiTaRS; GALC; human.
DR   GeneWiki; Galactosylceramidase; -.
DR   GenomeRNAi; 2581; -.
DR   PRO; PR:P54803; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; ENSG00000054983; -.
DR   CleanEx; HS_GALC; -.
DR   ExpressionAtlas; P54803; baseline and differential.
DR   Genevisible; P54803; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0043202; C:lysosomal lumen; TAS:Reactome.
DR   GO; GO:0005764; C:lysosome; TAS:ProtInc.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0004336; F:galactosylceramidase activity; ISS:UniProtKB.
DR   GO; GO:0006683; P:galactosylceramide catabolic process; ISS:UniProtKB.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; TAS:Reactome.
DR   InterPro; IPR001286; Glyco_hydro_59.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   PANTHER; PTHR15172; PTHR15172; 1.
DR   Pfam; PF02057; Glyco_hydro_59; 1.
DR   PRINTS; PR00850; GLHYDRLASE59.
DR   SUPFAM; SSF51445; SSF51445; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Complete proteome; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Glycoprotein; Glycosidase;
KW   Hydrolase; Leukodystrophy; Lipid degradation; Lipid metabolism;
KW   Lysosome; Polymorphism; Reference proteome; Signal;
KW   Sphingolipid metabolism.
FT   SIGNAL        1     42       {ECO:0000269|PubMed:8281145,
FT                                ECO:0000269|PubMed:8399327}.
FT   CHAIN        43    685       Galactocerebrosidase.
FT                                /FTId=PRO_0000012230.
FT   ACT_SITE    198    198       Proton donor/acceptor. {ECO:0000250}.
FT   ACT_SITE    274    274       Nucleophile. {ECO:0000250}.
FT   BINDING     109    109       Substrate. {ECO:0000250}.
FT   BINDING     151    151       Substrate. {ECO:0000250}.
FT   BINDING     197    197       Substrate. {ECO:0000250}.
FT   BINDING     396    396       Substrate. {ECO:0000250}.
FT   CARBOHYD    143    143       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    379    379       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    403    403       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    556    556       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    559    559       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    602    602       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID    287    394       {ECO:0000250}.
FT   VAR_SEQ       1     65       MAEWLLSASWQRRAKAMTAAAGSAGRAAVPLLLCALLAPGG
FT                                AYVLDDSDGLGREFDGIGAVSGGG -> MLGKSHGRATHGP
FT                                LPLADLGIHLPCVKVLHQVTPEEKPA (in isoform
FT                                4). {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_036974.
FT   VAR_SEQ       1     65       MAEWLLSASWQRRAKAMTAAAGSAGRAAVPLLLCALLAPGG
FT                                AYVLDDSDGLGREFDGIGAVSGGG -> MGFMVADLW (in
FT                                isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_036975.
FT   VAR_SEQ      66     88       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_036976.
FT   VAR_SEQ     638    685       GHFTSGMLNDKSLWTDIPVNFPKNGWAAIGTHSFEFAQFDN
FT                                FLVEATR -> VAGRRKKT (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_036977.
FT   VARIANT      21     21       A -> P (in dbSNP:rs111887056).
FT                                {ECO:0000269|PubMed:20886637}.
FT                                /FTId=VAR_064430.
FT   VARIANT      41     41       G -> S (in GLD; dbSNP:rs387906955).
FT                                {ECO:0000269|PubMed:17579360}.
FT                                /FTId=VAR_064431.
FT   VARIANT      59     59       G -> R (in GLD; infantile; significant
FT                                reduction of activity).
FT                                {ECO:0000269|PubMed:10234611}.
FT                                /FTId=VAR_013956.
FT   VARIANT      68     68       S -> F (in GLD; infantile; significant
FT                                reduction of activity).
FT                                {ECO:0000269|PubMed:10234611}.
FT                                /FTId=VAR_013957.
FT   VARIANT      79     79       R -> H (in GLD; dbSNP:rs370117160).
FT                                {ECO:0000269|PubMed:8940268}.
FT                                /FTId=VAR_013958.
FT   VARIANT      82     82       I -> M (in GLD; adult; reduction of
FT                                activity; when associated with V-2105).
FT                                {ECO:0000269|PubMed:9272171}.
FT                                /FTId=VAR_013959.
FT   VARIANT     111    111       G -> D (in GLD; dbSNP:rs746487628).
FT                                /FTId=VAR_003380.
FT   VARIANT     111    111       G -> S (in GLD; dbSNP:rs756690487).
FT                                {ECO:0000269|PubMed:8940268}.
FT                                /FTId=VAR_003381.
FT   VARIANT     112    112       T -> A (in GLD; adult;
FT                                dbSNP:rs147313927).
FT                                /FTId=VAR_003382.
FT   VARIANT     117    117       M -> L (in GLD; adult).
FT                                {ECO:0000269|PubMed:8940268}.
FT                                /FTId=VAR_003383.
FT   VARIANT     130    130       E -> K (in GLD; dbSNP:rs374635469).
FT                                {ECO:0000269|PubMed:20886637}.
FT                                /FTId=VAR_064432.
FT   VARIANT     184    184       R -> C (in dbSNP:rs1805078).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:20886637,
FT                                ECO:0000269|PubMed:7581365}.
FT                                /FTId=VAR_013960.
FT   VARIANT     187    187       D -> V (in GLD).
FT                                /FTId=VAR_003384.
FT   VARIANT     194    194       G -> A (in GLD).
FT                                /FTId=VAR_003385.
FT   VARIANT     248    248       D -> N (in dbSNP:rs34362748).
FT                                {ECO:0000269|PubMed:20886637}.
FT                                /FTId=VAR_003386.
FT   VARIANT     250    250       I -> T (in GLD; late infantile).
FT                                {ECO:0000269|PubMed:8940268}.
FT                                /FTId=VAR_003387.
FT   VARIANT     263    263       A -> T (in GLD).
FT                                /FTId=VAR_003388.
FT   VARIANT     278    278       T -> I (in GLD; infantile; significant
FT                                reduction of activity).
FT                                {ECO:0000269|PubMed:10234611}.
FT                                /FTId=VAR_013961.
FT   VARIANT     284    284       G -> S (in GLD; dbSNP:rs377274761).
FT                                {ECO:0000269|PubMed:8940268}.
FT                                /FTId=VAR_003389.
FT   VARIANT     286    286       G -> D (in GLD; significant reduction of
FT                                activity; dbSNP:rs199847983).
FT                                {ECO:0000269|PubMed:10477434,
FT                                ECO:0000269|PubMed:9272171}.
FT                                /FTId=VAR_003390.
FT   VARIANT     295    295       N -> T (in GLD; dbSNP:rs746922378).
FT                                /FTId=VAR_003391.
FT   VARIANT     303    303       S -> F (in GLD; infantile;
FT                                dbSNP:rs756352952).
FT                                /FTId=VAR_003392.
FT   VARIANT     305    305       I -> V (in dbSNP:rs1805079).
FT                                {ECO:0000269|PubMed:9272171}.
FT                                /FTId=VAR_013962.
FT   VARIANT     314    314       Y -> C (in GLD).
FT                                {ECO:0000269|PubMed:8940268}.
FT                                /FTId=VAR_013963.
FT   VARIANT     318    318       P -> A (in GLD).
FT                                {ECO:0000269|PubMed:8595408}.
FT                                /FTId=VAR_003393.
FT   VARIANT     318    318       P -> R (in GLD; dbSNP:rs387906954).
FT                                {ECO:0000269|PubMed:20886637}.
FT                                /FTId=VAR_064433.
FT   VARIANT     323    323       G -> R (in GLD).
FT                                {ECO:0000269|PubMed:20886637}.
FT                                /FTId=VAR_064434.
FT   VARIANT     335    335       Y -> C (in GLD; infantile; significant
FT                                reduction of activity;
FT                                dbSNP:rs757407613).
FT                                {ECO:0000269|PubMed:10234611}.
FT                                /FTId=VAR_013964.
FT   VARIANT     384    384       I -> T (in GLD).
FT                                {ECO:0000269|PubMed:20886637}.
FT                                /FTId=VAR_064435.
FT   VARIANT     396    396       R -> L (in GLD).
FT                                {ECO:0000269|PubMed:20886637}.
FT                                /FTId=VAR_064436.
FT   VARIANT     396    396       R -> W (in GLD; bilateral cherry red
FT                                spots; dbSNP:rs770485731).
FT                                /FTId=VAR_003394.
FT   VARIANT     400    400       P -> L (in GLD).
FT                                /FTId=VAR_003395.
FT   VARIANT     426    426       W -> G (in GLD; infantile; significant
FT                                reduction of activity).
FT                                {ECO:0000269|PubMed:10234611}.
FT                                /FTId=VAR_013965.
FT   VARIANT     468    468       T -> S (in GLD; dbSNP:rs34134328).
FT                                /FTId=VAR_003396.
FT   VARIANT     490    490       Y -> N (in GLD; dbSNP:rs202135871).
FT                                {ECO:0000269|PubMed:20886637}.
FT                                /FTId=VAR_064437.
FT   VARIANT     514    514       F -> S (in GLD; dbSNP:rs375867319).
FT                                /FTId=VAR_003397.
FT   VARIANT     529    529       T -> M (in GLD; infantile;
FT                                dbSNP:rs200960659).
FT                                /FTId=VAR_003398.
FT   VARIANT     531    531       R -> C (in GLD; dbSNP:rs749893889).
FT                                /FTId=VAR_003399.
FT   VARIANT     531    531       R -> H (in GLD; infantile; significant
FT                                reduction of activity;
FT                                dbSNP:rs200378205).
FT                                {ECO:0000269|PubMed:10234611}.
FT                                /FTId=VAR_013966.
FT   VARIANT     544    544       D -> N (in GLD; Arab patients;
FT                                dbSNP:rs387906952).
FT                                {ECO:0000269|PubMed:8786069}.
FT                                /FTId=VAR_003400.
FT   VARIANT     553    553       G -> R (in GLD; loss of activity;
FT                                dbSNP:rs748573754).
FT                                {ECO:0000269|PubMed:10477434}.
FT                                /FTId=VAR_013967.
FT   VARIANT     562    562       I -> T (common polymorphism;
FT                                dbSNP:rs398607).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:20886637,
FT                                ECO:0000269|PubMed:7601472,
FT                                ECO:0000269|PubMed:8940268,
FT                                ECO:0000269|PubMed:9272171}.
FT                                /FTId=VAR_003401.
FT   VARIANT     566    566       V -> G (in GLD).
FT                                {ECO:0000269|PubMed:8595408}.
FT                                /FTId=VAR_003402.
FT   VARIANT     567    567       Y -> S (in GLD; dbSNP:rs752537626).
FT                                /FTId=VAR_003403.
FT   VARIANT     592    592       A -> S (in GLD).
FT                                /FTId=VAR_003404.
FT   VARIANT     599    599       I -> S (in GLD; infantile; Druze
FT                                patients; dbSNP:rs387906953).
FT                                {ECO:0000269|PubMed:8786069}.
FT                                /FTId=VAR_003405.
FT   VARIANT     634    634       L -> S (in GLD; adult;
FT                                dbSNP:rs138577661).
FT                                {ECO:0000269|PubMed:9272171}.
FT                                /FTId=VAR_013968.
FT   VARIANT     641    641       T -> A (in dbSNP:rs421262).
FT                                {ECO:0000269|PubMed:10477434,
FT                                ECO:0000269|PubMed:12508121,
FT                                ECO:0000269|PubMed:20886637}.
FT                                /FTId=VAR_003406.
FT   VARIANT     645    645       L -> R (in GLD; adult;
FT                                dbSNP:rs780593419).
FT                                /FTId=VAR_003407.
FT   VARIANT     668    668       T -> R (in GLD; infantile; significant
FT                                reduction of activity).
FT                                {ECO:0000269|PubMed:10234611}.
FT                                /FTId=VAR_013969.
FT   VARIANT     681    681       V -> M (in GLD; dbSNP:rs200607029).
FT                                {ECO:0000269|PubMed:23462331}.
FT                                /FTId=VAR_069512.
FT   CONFLICT     78     78       Y -> H (in Ref. 1; BAH13778).
FT                                {ECO:0000305}.
FT   CONFLICT    195    195       I -> T (in Ref. 3; BAG64110).
FT                                {ECO:0000305}.
FT   CONFLICT    422    422       E -> G (in Ref. 3; BAG64110).
FT                                {ECO:0000305}.
SQ   SEQUENCE   685 AA;  77063 MW;  03F3D223381AD5B1 CRC64;
     MAEWLLSASW QRRAKAMTAA AGSAGRAAVP LLLCALLAPG GAYVLDDSDG LGREFDGIGA
     VSGGGATSRL LVNYPEPYRS QILDYLFKPN FGASLHILKV EIGGDGQTTD GTEPSHMHYA
     LDENYFRGYE WWLMKEAKKR NPNITLIGLP WSFPGWLGKG FDWPYVNLQL TAYYVVTWIV
     GAKRYHDLDI DYIGIWNERS YNANYIKILR KMLNYQGLQR VKIIASDNLW ESISASMLLD
     AELFKVVDVI GAHYPGTHSA KDAKLTGKKL WSSEDFSTLN SDMGAGCWGR ILNQNYINGY
     MTSTIAWNLV ASYYEQLPYG RCGLMTAQEP WSGHYVVESP VWVSAHTTQF TQPGWYYLKT
     VGHLEKGGSY VALTDGLGNL TIIIETMSHK HSKCIRPFLP YFNVSQQFAT FVLKGSFSEI
     PELQVWYTKL GKTSERFLFK QLDSLWLLDS DGSFTLSLHE DELFTLTTLT TGRKGSYPLP
     PKSQPFPSTY KDDFNVDYPF FSEAPNFADQ TGVFEYFTNI EDPGEHHFTL RQVLNQRPIT
     WAADASNTIS IIGDYNWTNL TIKCDVYIET PDTGGVFIAG RVNKGGILIR SARGIFFWIF
     ANGSYRVTGD LAGWIIYALG RVEVTAKKWY TLTLTIKGHF TSGMLNDKSL WTDIPVNFPK
     NGWAAIGTHS FEFAQFDNFL VEATR
//
